Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Other financing activities (2023 - 2025)

ArriVent BioPharma has reported Other financing activities over the past 2 years, most recently at $17000.0 for Q4 2025.

  • Quarterly results put Other financing activities at $17000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $70000.0 (changed N/A YoY), and the annual figure for FY2025 was $70000.0, changed.
  • Other financing activities reached $17000.0 in Q4 2025 per AVBP's latest filing, up from -$300000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $1.3 million in Q4 2023 and bottomed at -$300000.0 in Q3 2025.